GLP-1 Medicines and Idiopathic Intracranial Hypertension: What the Exenatide Trial and Cohort Studies Show

Can GLP-1 medicines help idiopathic intracranial hypertension? The early evidence says they might. A small randomized trial found exenatide lowered the pressure around the brain within hours, and record-based studies of liraglutide, semaglutide and tirzepatide link them to less optic nerve swelling and fewer headaches. No GLP-1 medicine is approved for the condition, and the best data so far come from 16 women.

Idiopathic intracranial hypertension, usually shortened to IIH, means the cerebrospinal fluid around the brain sits at high pressure with no tumour or blockage to explain it. The pressure causes headaches and can swell the optic nerves, a sign called papilledema, which puts vision at risk. Weight loss is the main way to change the course of the disease, which is how a drug class built for diabetes and obesity entered the picture.

This article covers who gets IIH, why weight matters so much, what the exenatide trial measured, what the larger cohort studies and meta-analyses found, and what is still unknown, including whether anyone has tested a low dose.

Who gets idiopathic intracranial hypertension?

14-year population study, Journal of Neurology, 2026

Idiopathic intracranial hypertension mainly affects women of reproductive age who carry excess weight. A 14-year study from two Melbourne hospitals, covering most cases in the Australian state of Victoria, identified 504 adults with IIH. Of those adults, 94% were female, the mean age was 28.0 and the mean BMI was 37.6. Headache was the presenting symptom in 84%.

IIH is also becoming more common. In women aged 18-39, the group with the highest rates, incidence in Victoria rose from 0.11 per 100,000 in 2010 to 6.79 per 100,000 in 2023. The authors said the rise mirrors trends reported in other countries and tracks with obesity, though a population study cannot prove the cause.

Why does weight loss matter so much in IIH?

IIH Weight Trial, Mollan and colleagues, JAMA Neurology, 2021

Weight loss is the one treatment shown in a randomized trial to lower intracranial pressure and keep it down. UK consensus guidelines published in 2018 set out three principles for managing IIH: treat the underlying disease, protect vision and minimise headache. Treating the underlying disease, in practice, has meant weight loss.

The IIH Weight Trial put that to the test. Researchers at 5 UK hospitals randomized 66 women with active IIH and a BMI of 35 or higher to bariatric surgery (33 women) or a community weight management programme, Weight Watchers (33 women). Compared with the weight management group, intracranial pressure was 6.0 cmCSF lower at 12 months and 8.2 cmCSF lower at 24 months after surgery. Weight was 21.4 kg and 26.6 kg lower.

A follow-up analysis in Neurology looked at how much weight loss was needed. The greater the weight loss, the greater the fall in pressure, and about 24% weight loss was associated with remission, meaning a pressure of 25 cmCSF or lower. The women started at a mean lumbar puncture pressure of 34.4 and 34.9 cmCSF in the two groups. The authors concluded that this much weight loss was unlikely without surgery, which is the gap GLP-1 medicines might help fill. Our article on GLP-1 medicines after bariatric surgery covers how the two approaches are being combined.

What did the exenatide trial for IIH find?

Mitchell and colleagues, Brain, 2023

The exenatide trial found that the GLP-1 medicine lowered intracranial pressure within hours and kept it lower for 12 weeks. The University of Birmingham team enrolled 16 women with active IIH, defined as pressure above 25 cmCSF plus papilloedema, and 15 completed the study. They averaged 28 years old, with a BMI of 38.1 and a starting pressure of 30.6 cmCSF.

Each woman had a telemetric pressure catheter implanted, so the team could track brain pressure continuously rather than relying on repeated lumbar punctures. Compared with placebo, exenatide lowered pressure by 5.7 cmCSF at 2.5 hours, 6.4 cmCSF at 24 hours and 5.6 cmCSF at 12 weeks. No serious safety signals were noted.

Two caveats matter. The trial was tiny, and the investigators set the bar for significance at 0.1 rather than the usual 0.05, which suits an early proof-of-concept study. The 12-week result, with a P value of 0.058, cleared that bar but would not have cleared the conventional one. The 2.5-hour drop is the more striking finding, because no meaningful weight loss can happen that fast.

Do GLP-1 medicines work in IIH only through weight loss?

What the speed of the effect suggests

GLP-1 medicines probably affect IIH through more than weight loss alone, although this is not proven in people. The exenatide effect at 2.5 hours points to a direct action on pressure. The Stefanou meta-analysis in the European Journal of Neurology cites animal evidence that GLP-1 signalling reduces cerebrospinal fluid secretion.

That matters because weight loss on its own takes months to build, while IIH can damage the optic nerve faster than that. A medicine that lowers pressure quickly and also drives weight loss would cover both timescales. Whether GLP-1 medicines actually deliver both in a properly sized trial has not been shown. For the broader headache picture on these drugs, see our article on headaches on a GLP-1.

Do semaglutide and liraglutide help IIH headaches and weight?

Krajnc and colleagues, Journal of Headache and Pain, 2023

A small Vienna pilot study found semaglutide or liraglutide produced far more weight loss and fewer headache days than usual care alone. The study included 39 patients with IIH, with a mean age of 33.6 and a median BMI of 36.3. Thirteen chose a GLP-1 medicine on top of usual weight management, and the rest served as matched controls.

At six months, mean weight loss was 12.0% on a GLP-1 medicine against 2.8% on usual care, and 69.2% versus 4.0% had lost 10% or more. Monthly headache days fell by a median of 4 against 0, and 76.9% versus 40.0% halved their headache days. Patients on a GLP-1 medicine also cut their acetazolamide dose by a median of 16.5%.

Vision measures did not change significantly in either group over six months. Side effects were mild or moderate and mostly gastrointestinal, reported by 9 of the 13 GLP-1 patients, and none stopped early because of them. Patients chose their own group, so people more motivated to lose weight may have ended up on the drug.

What do the liraglutide and tirzepatide cohort studies show?

Azzam and colleagues, 2025, TriNetX health records

Two record-based studies from the same Montefiore-Einstein team link GLP-1 medicines to less papilledema in IIH. Both used propensity score matching to pair patients on a GLP-1 medicine with similar patients on standard care alone.

The liraglutide study in the Annals of Clinical and Translational Neurology compared 204 patients with 204 controls, nearly all women (95.1% and 97.1%). Papilledema risk was lower on liraglutide at 3 months (risk ratio 0.333) and still lower at 24 months (0.524). Visual and headache outcomes improved too, but those differences were not statistically significant.

The tirzepatide study in Endocrinology, Diabetes & Metabolism matched 193 patients with 193 controls. At 24 months it reported a 68% lower risk of papilledema, a 73.9% lower risk of visual disturbance or blindness and a 19.7% lower risk of headache. BMI fell by 1.147 kg/m² more than in controls. Health record studies cannot account for everything that differs between patients who are and are not prescribed a drug, so these are associations rather than proof. Our guide to GLP-1 medicines and eye health covers the separate optic nerve concerns raised about these drugs.

What do the meta-analyses of GLP-1 medicines in IIH say?

Stefanou, European Journal of Neurology, 2025; Falcão, Headache, 2026

Both meta-analyses found GLP-1 medicines were linked to less papilledema and visual disturbance, and both warned the evidence is early. The Stefanou review pooled 1550 IIH patients, 768 of them on a GLP-1 or GIP/GLP-1 medicine. Papilledema risk was lower (risk ratio 0.25), and so was the risk of visual disturbance (0.41). Headache risk showed a trend that did not reach significance (0.61), but monthly headache days fell by 3.64 at 3 months and 4.82 by the end of follow-up.

The larger 2026 Falcão review in Headache pooled 8 studies and 13,243 patients. Risk ratios at 3 and 24 months were 0.430 and 0.469 for papilledema, 0.408 and 0.433 for visual disturbance, and 0.690 and 0.796 for headache. A risk ratio below 1 means the outcome was less common on a GLP-1 medicine.

The Falcão authors were blunt about the limits: the evidence base is dominated by observational studies with moderate to serious risk of confounding, so the findings are low certainty and should guide future trials rather than practice. Side effects were the familiar ones. In the Stefanou review, mild gastrointestinal effects and nausea occurred in 88% of treated patients, with no serious adverse events or treatment discontinuations reported.

Should someone with IIH ask about a GLP-1 medicine?

Where the evidence leaves patients

Someone with IIH and obesity can reasonably raise GLP-1 medicines with their neurologist, as long as the conversation reflects how early the evidence is. The strongest data are a 16-woman randomized trial and record-based studies. A large randomized trial measuring vision, pressure and headaches over years has not yet been reported.

IIH also shares ground with other conditions common in young women with obesity, such as polycystic ovary syndrome, which our article on GLP-1 medicines and PCOS covers. Any GLP-1 medicine in IIH sits alongside, not in place of, eye monitoring and the standard treatments a specialist prescribes, because papilledema can progress without obvious symptoms.

Has a GLP-1 microdose been tested for IIH?

What the evidence can and cannot support

No. None of the IIH studies covered here tested low maintenance doses. The exenatide trial used a dose set by the investigators, and the cohort studies captured whatever doses treating doctors prescribed. None reported IIH outcomes by dose level.

The rapid pressure drop seen with exenatide raises a fair question about whether a lower dose could act on pressure without full-dose side effects. Nobody has measured that. And if weight loss is a large part of the benefit, the IIH Weight Trial suggests a lot of weight loss is needed, which points away from minimal dosing rather than towards it.

IIH can cause permanent vision loss. Anyone with the condition should be managed by a neurologist or neuro-ophthalmologist, with regular eye checks, rather than experimenting with a GLP-1 dose on their own.

Frequently Asked Questions